GlassScriptPhysician profile
Gregory M Fuller
NPI 1356347306
$26,781.13
in general payments reported to CMS, 2019-2025
68 companies · $3,468 in 2025
The $3,468 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,452 · 2020: $2,364 · 2021: $4,840 · 2022: $2,495 · 2023: $2,406 · 2024: $2,757 · 2025: $3,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,811 · Consulting Fee: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,811.06 |
| Consulting Fee | $1,820.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,286.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $2,325.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $2,122.04 | 2019-2025 | |
| Shionogi INC | $1,820.00 | 2025 | S-217622 |
| Astrazeneca Pharmaceuticals LP | $1,474.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,459.13 | 2021 | |
| Novo Nordisk INC | $1,331.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,295.32 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $1,205.11 | 2019-2025 | |
| Amgen INC. | $1,193.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.32 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $596.80 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $477.46 | 2023-2025 | Voquezna |
| Seqirus USA INC | $462.99 | 2019-2022 | |
| Chugai Pharmaceutical Co., LTD. | $400.00 | 2021 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $369.33 | 2023-2024 | Qelbree, Qelbree, Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.20 | 2019-2024 | Cycloset, Xifaxan, Trulance |
| Allergan, INC. | $348.44 | 2019-2020 | |
| Antares Pharma, INC. | $341.35 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Idorsia Pharmaceuticals US INC | $326.18 | 2022-2025 | Quviviq, Quviviq |
| Eisai INC. | $295.54 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.68 | 2020-2022 | |
| Astellas Pharma US INC | $248.41 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $243.50 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $221.46 | 2019-2023 | Xarelto |
| Inspire Medical Systems, INC. | $188.95 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $183.17 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $173.35 | 2022-2023 | Trudhesa |
| Genentech USA, INC. | $164.50 | 2019-2022 | |
| Exact Sciences Corporation | $147.60 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $138.33 | 2021-2022 | |
| Dexcom, INC. | $135.97 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $111.13 | 2022 | |
| Halozyme INC | $101.91 | 2023 | |
| Abbott Laboratories | $96.63 | 2022-2024 | Freestyle Libre 2, Jot Dx, Assurity |
| Sanofi Pasteur INC. | $83.80 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $82.27 | 2023-2024 | Rexulti |
| Avvisto Therapeutics, LLC | $77.91 | 2024-2025 | Cycloset |
| Upsher-Smith Laboratories LLC | $73.13 | 2020-2023 | |
| Scilex Pharmaceuticals INC. | $72.22 | 2019-2022 | |
| Medtronic, INC. | $66.47 | 2022-2024 | Venaseal, Intellis Adaptivestim |
| Organon LLC | $64.28 | 2022 | |
| Merck Sharp & Dohme LLC | $59.02 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Kaleo, INC. | $54.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.63 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $51.03 | 2021-2025 | Nuzyra |
| Shield Therapeutics INC | $49.31 | 2024 | |
| Optinose US, INC. | $46.84 | 2023 | |
| Currax Pharmaceuticals LLC | $46.42 | 2024-2025 | Contrave, Onzetra Xsail |
| Alk-Abello, INC | $43.56 | 2023-2025 | Neffy, Ragwitek, Odactra |
| Ironwood Pharmaceuticals, INC | $38.61 | 2020 | |
| Arbor Pharmaceuticals, INC. | $32.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $31.68 | 2023-2024 | Nexletol |
| Optos, INC. | $30.70 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $29.38 | 2024 | Tlando |
| Regeneron Healthcare Solutions, INC. | $28.29 | 2019 | |
| Philips North America LLC | $22.17 | 2024 | (Ck7) Extended Holter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.98 | 2025 | Caplyta |
| Adlon Therapeutics L.P. | $14.63 | 2020 | |
| Tolmar, INC. | $14.54 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2023 | Livalo |
| Mdd US Operations, LLC | $11.26 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$913.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.